Key result
Ambulatory levosimendan in advanced HFrEF is linked to significant GDMT uptitration at one year.
Why the study?
It was unclear whether intermittent ambulatory levosimendan infusions could facilitate the titration of guideline-directed medical therapy in patients with advanced HFrEF intolerant to target doses.
Do intermittent ambulatory levosimendan infusions improve the uptitration of guideline-directed medical therapy in patients with advanced HFrEF?
Observational (n=37)
No
Do intermittent ambulatory levosimendan infusions improve the uptitration of guideline-directed medical therapy in patients with advanced HFrEF?
Intermittent ambulatory levosimendan infusions may facilitate the uptitration of guideline-directed medical therapy and reduction of diuretic doses in patients with advanced HFrEF.
Answers are grounded in this paper and cite their sources.
May aid GDMT uptitration in advanced HFrEF; leaves open causality and needs RCTs before adoption.
Background: Patients with advanced heart failure with reduced ejection fraction often cannot tolerate target doses of guideline-directed medical therapy due to symptomatic hypotension, renal dysfunction, and associated electrolyte abnormalities. While levosimendan can facilitate the titration of β-blockers in patients with advanced HFrEF, it is unclear whether ambulatory levosimendan infusions would offer the same benefit. In this prospective study, we investigate the effects of intermittent ambulatory levosimendan infusions on the uptitration of disease-modifying drugs. Methods: We enrolled 37 patients with advanced HFrEF who received repeated ambulatory infusions of levosimendan between January 2018 and January 2021. The demographic, clinical, and laboratory data were acquired 24 h before the first and the last ambulatory levosimendan infusion. Results: At the 1 year follow-up, the enrolled patients were on significantly higher doses of guideline-directed medical therapy, including bisoprolol (3.2 ± 2.8 mg vs. 5.9 ± 4.1 mg; p = 0.02), sacubitril/valsartan (41.67 ± 32.48 mg vs. 68.5 ± 35.72 mg; p = 0.01), and eplerenone (12.7 ± 8.5 mg vs. 22.8 ± 13.6 mg; p = 0.03). Furthermore, a substantial decrease in the furosemide dose was observed (123.2 ± 32.48 mg vs. 81.6 ± 19.47 mg; p < 0.0001). Conclusions: Levosimendan facilitates the optimization of disease-modifying heart failure medications in previously intolerant advanced HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Masarone et al. (2022) conducted an observational in Advanced heart failure with reduced ejection fraction (HFrEF) (n=37). Intermittent ambulatory levosimendan infusions vs. Baseline was evaluated on Uptitration of disease-modifying drugs (guideline-directed medical therapy). Ambulatory levosimendan infusions in advanced HFrEF patients increased bisoprolol doses from 3.2 to and sacubitril/valsartan from 41.67 to at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: